Information Provided By: 
Fly News Breaks for July 26, 2017
DGX
Jul 26, 2017 | 08:17 EDT
Canaccord analyst Mark Massaro said Quest Diagnostics delivered solid Q2 results and raised its guidance. He believes Quest is well positioned to achieve growth from acquisitions, develop higher fee cash flow, and continue stock buybacks. Massaro said yesterday's modest pullback is overdone and he reiterated his Buy rating and $118 price target on Quest Diagnostics shares.
News For DGX From the Last 2 Days
DGX
Apr 25, 2024 | 05:10 EDT
DGX
Apr 24, 2024 | 09:46 EDT
DGX
Apr 24, 2024 | 09:10 EDT
DGX
Apr 24, 2024 | 06:55 EDT
UBS raised the firm's price target on Quest Diagnostics to $146 from $139 and keeps a Neutral rating on the shares. UBS is more confident that Quest can hit its margin expansion story following the Q2 print and the firm's call with management, the analyst tells investors in a research note. Labor cost trends seem to have already peaked and Covid revenues should no longer be a headwind starting 2H, while above market base volume growth continues, the firm notes.
DGX
Apr 24, 2024 | 06:43 EDT
DGX
Apr 24, 2024 | 06:24 EDT
Citi raised the firm's price target on Quest Diagnostics to $145 from $135 and keeps a Neutral rating on the shares post the Q1 report. The company increased the midpoint of its fiscal 2024 revenue target and management anticipates the rest of fiscal year to follow regular seasonality on a revenue and margin basis with a step-up into Q2, the analyst tells investors in a research note.
DGX
Apr 23, 2024 | 09:04 EDT
Check out this morning's top movers from around Wall Street, compiled by The Fly. UP AFTER EARNINGS... To see the rest of the story go to thefly.com. See Story Here
DGX
Apr 23, 2024 | 06:50 EDT
